内容紹介
Summary
TAS-102 has been administered to patients with unresectable colorectal cancer. We initiated TAS-102 administration in 2014 and gradually increased the number of indications. In a global, multicenter, randomized, double-blind, phase Ⅲ study(RECOURSE study), TAS-102 administration improved overall survival by 1.8 months and progression-free survival by 0.3 months compared with those in the placebo group. However, there are limited clinical reports of long-term administration of TAS-102. We encountered 2 cases of continuous long-term use of the TAS-102 for over 2 years. In our cases, although the cancer had been recognized early as exhibiting slow growth during follow-up, the physical symptoms did not appear for an extended period. Although grade 3 neutropenia was pointed out several times during the follow-up term, severe digestive symptoms had not occurred. Therefore, the patients could remain motivated to receive the drug. In our cases, the adequate treatment for neutropenia enabled long-term administration of TAS-102; therefore, TAS-102 would be tolerable for patients of colorectal cancer after receiving chemotherapy for an extended period.
要旨
トリフルリジン・チピラシル塩酸塩配合錠(Lonsurf®: TAS-102)は切除不能進行再発大腸癌の適応症を取得し,市販開始より約3年が経過したが,長期にわたる使用実績については不明である。今回当院では,進行再発結腸,直腸癌患者に対し2年を超えるTAS-102連続使用例を2例経験した。経過中緩徐な増大傾向でありながらも増大に伴う身体症状が出現するまでにいずれも内服開始から2年以上を要している。主な副作用として複数回の好中球減少を認め減薬,休薬期間の延長などを必要としたが消化器症状などの出現はなく,継続的に内服可能であった。TAS-102は比較的忍容性が高く,高齢者または強力な化学療法投与後の担癌患者において安全で有効な治療選択肢であると考えられた。
目次
TAS-102 has been administered to patients with unresectable colorectal cancer. We initiated TAS-102 administration in 2014 and gradually increased the number of indications. In a global, multicenter, randomized, double-blind, phase Ⅲ study(RECOURSE study), TAS-102 administration improved overall survival by 1.8 months and progression-free survival by 0.3 months compared with those in the placebo group. However, there are limited clinical reports of long-term administration of TAS-102. We encountered 2 cases of continuous long-term use of the TAS-102 for over 2 years. In our cases, although the cancer had been recognized early as exhibiting slow growth during follow-up, the physical symptoms did not appear for an extended period. Although grade 3 neutropenia was pointed out several times during the follow-up term, severe digestive symptoms had not occurred. Therefore, the patients could remain motivated to receive the drug. In our cases, the adequate treatment for neutropenia enabled long-term administration of TAS-102; therefore, TAS-102 would be tolerable for patients of colorectal cancer after receiving chemotherapy for an extended period.
要旨
トリフルリジン・チピラシル塩酸塩配合錠(Lonsurf®: TAS-102)は切除不能進行再発大腸癌の適応症を取得し,市販開始より約3年が経過したが,長期にわたる使用実績については不明である。今回当院では,進行再発結腸,直腸癌患者に対し2年を超えるTAS-102連続使用例を2例経験した。経過中緩徐な増大傾向でありながらも増大に伴う身体症状が出現するまでにいずれも内服開始から2年以上を要している。主な副作用として複数回の好中球減少を認め減薬,休薬期間の延長などを必要としたが消化器症状などの出現はなく,継続的に内服可能であった。TAS-102は比較的忍容性が高く,高齢者または強力な化学療法投与後の担癌患者において安全で有効な治療選択肢であると考えられた。